The Novel Oral mTORC1/2 Inhibitor TAK-228 Reverses Trastuzumab Resistance in HER2-Positive Breast Cancer Models.

Cancers (Basel) · 2021 · PMC8199905 · PMID 34204960

Europe PMC DOI

hedged sentence

0.0100

closest p · 0.2× alpha

0.0100

boldest claim

The sentences

highly significantp -value < 0.01actually significant

BT-474.rT3 cells showed a highly significant decrease in proliferation in the trastuzumab and TAK-228 condition (52%) compared to trastuzumab (84%, p -value < 0.01) and TAK-228 (67%, p -value < 0.01).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.